The Plaque Psoriasis (Psoriasis Vulgaris) Pipeline 2016 Market Report
PUNE, India, May 20, 2016 /PRNewswire/ --
ReportsnReports.com adds "Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016" market research report with comprehensive information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects.
Complete report on H1 2016 pipeline review of Plaque Psoriasis (Psoriasis Vulgaris) with 85 market data tables and 15 figures, spread across 334 pages is available at http://www.reportsnreports.com/reports/543635-plaque-psoriasis-psoriasis-vulgaris-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review, H1 2016 report include 3SBio Inc., AbGenomics International, Inc., Almirall, S.A., Amgen Inc., AstraZeneca Plc, Avexxin AS, BIOCAD, Biocon Limited, Bionovis SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Can-Fite BioPharma Ltd., Celgene Corporation, Cellceutix Corporation, Celltrion, Inc., Clonz Biotech Private Limited, Coherus BioSciences, Inc., Delenex Therapeutics AG, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Forward Pharma A/S, Galectin Therapeutics, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, Idera Pharmaceuticals, Inc., Invion Limited, Johnson & Johnson, Kadmon Corporation, LLC, Kineta, Inc., Kyowa Hakko Kirin Co., Ltd., LEO Pharma A/S, Lipidor AB, Mabion SA, Maruho Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oncobiologics, Inc., Pfizer Inc., Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Provectus Biopharmaceuticals, Inc., Sandoz International GmbH, Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., Takeda Pharmaceutical Company Limited, TetraLogic Pharmaceuticals, Therapeutic Proteins International, LLC, UCB S.A., Valeant Pharmaceuticals International, Inc., XBiotech USA, Inc. and Ziarco Pharma Ltd.
Drug Profiles discussed in this research are (betamethasone dipropionate + calcipotriene), (betamethasone valerate + calcipotriene), (halobetasol propionate + tazarotene), AbGn-168H, adalimumab biosimilar, AM-001, amiselimod hydrochloride, AVX-001, baricitinib, bimekizumab, bleselumab, BMS-986165, brodalumab, BTX-1308, C-82, calcipotriene, CC-90005, certolizumab pegol, CJM-112, dalazatide, DFD-01, DFD-06, dimethyl fumarate, DLX-105, DNX-114, etanercept, etanercept biosimilar, GK-664S, GRMD-02, GSK-2831781, GSK-2981278, guselkumab, IDP-122, IMO-8400, IMP-731, infliximab biosimilar, INV-103, ixekizumab, KD-025, KM-133, LEO-32731, LP-0113, M-7040, MC-201, namilumab, pefcalcitol, PF-06700841, PH-10, piclidenoson, RA-18C3, remetinostat, risankizumab, RTU-1096, seletalisib, tildrakizumab, tofacitinib, toreforant tartrate, ustekinumab biosimilar and ZPL-3893787. Order a copy of Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=543635 .
Another newly published market research report titled on Contact Dermatitis - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Contact Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contact Dermatitis and special features on late-stage and discontinued projects. Companies discussed in this research are Aldeyra Therapeutics, Inc., Anacor Pharmaceuticals, Inc., AskAt Inc., Brickell Biotech, Inc., Dr. August Wolff GmbH & Co. KG Arzneimittle, Hapten Sciences, Inc., ILiAD Biotechnologies, LLC, LegoChem Biosciences, Inc, Marinomed Biotechnologie GmbH, Novartis AG, Signum Dermalogix, Inc and Sucampo Pharmaceuticals, Inc. Contact Dermatitis Pipeline market research report of 75 pages is available at http://www.reportsnreports.com/reports/543661-contact-dermatitis-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Facebook:https://www.facebook.com/ReportsnReports/
LinkedIn:https://www.linkedin.com/company/reportsnreports
Twitter:https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+1 888 391 5441
[email protected]
Share this article